Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PD”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 235 records · Page 13Linked to original sources

[Eukaryotic expression and functional characterization of PD-1 extracellular domain].

The negative signal provided by interactions of costimulatory molecules, programmed death-1 (PD-1) and its ligands, PD-L1 (also B7-H1) and PD-L2 (also B7-DC), is involved in the mechanisms of tumor immune evasion. To block PD-Ls-PD-1 interactions by a soluble receptor of PD-1, we constructed a eukaryotic expression plasmid that expresses extracellular region (aa1-aa167) of murine PD-1 (pPD-1A) and, another version of pPD-1A, pPD-1B, carrying cDNAs encoding for both extracellular region of PD-1 and green fluorescent protein (GFP) reporter gene, which was inserted downstream of PD-1. Experiment of BHK cells transfected with pPD-1B determined that most expression product (sPD-1) in the cells was secreted out. FACS analysis revealed that sPD-1 was specific and bound efficiently to PD-1 ligands. Cytotoxicity assay showed that blocking PD-Ls on either tumor cells or spleen cells by sPD-1 mediated enhanced lysis of H22 cells by Hsp70-H22 peptides complexstimulated spleen cells. The constructed plasmid vector would provide a novel method of tumor gene therapy of blocking PD-Ls-PD-1 interactions by expression of soluble receptor of PD-1 in tumor sites, which could increase the antitumor activity.

Animals↗

No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation.

The B7 family member programmed-death-1-ligand 2 (PD-L2/B7-DC) is a ligand for programmed-death-receptor 1 (PD-1), a receptor involved in negative regulation of T cell activation. Several independent studies have reported that PD-L2, however, can also potently costimulate murine T cells via an additional yet unidentified receptor. In this study, we evaluated the contribution of PD-L2 to the activation of human T cells using a novel system of engineered T cell stimulators that expresses membrane-bound anti-CD3 antibodies. Analyzing early activation markers, cytokine production and proliferation, we found PD-L2 to consistently inhibit T cell activation. PD-L2 inhibition affected CD4+ and CD8+ T cells and was not abrogated by costimulation via CD28. Blocking PD-1 reverted the inhibitory effect of PD-L2, demonstrating involvement of this pathway. In human T cells, we found no evidence for any of the costimulatory effects described for PD-L2 in murine systems. In line with our functional data that do not point to stimulatory PD-L2-ligands, we show that binding of PD-L2-immunoglobulin to activated human T cells is abrogated by PD-1 antibodies. Our results demonstrate that PD-L2 negatively regulates human T cell activation and thus might be a candidate molecule for immunotherapeutic approaches aimed to attenuate pathological immune responses.

Antigens, CD↗

Biological control of the size and reactivity of catalytic Pd(0) produced by Shewanella oneidensis.

The interaction between Shewanella oneidensis MR-1 and the soluble metal Pd(II) during the reductive precipitation of Pd(0) determined the size and properties of the precipitated Pd(0) nanoparticles. Assessment of cell viability indicated that the bioreduction of Pd(II) was a detoxification mechanism depending on the Pd(II) concentration and on the presence and properties of the electron donor. The addition of H(2) in the headspace allowed S. oneidensis to resist the toxic effects of Pd(II). Interestingly, 25 mM formate was a less effective electron donor for bioreductive detoxification of Pd(II), since there was a 2 log reduction of culturable cells and a 20% decrease of viable cells within 60 min, followed by a slow recovery. When the ratio of Pd:cell dry weight (CDW) was below 5:2 at a concentration of 50 mg l(-1) Pd(II), most of the cells remained viable. These viable cells precipitated Pd(0) crystals over a relatively larger bacterial surface area and had a particle area that was up to 100 times smaller when compared to Pd(0) crystals formed on non-viable biomass (Pd:CDW ratio of 5:2). The relatively large and densely covering Pd(0) crystals on non-viable biomass exhibited high catalytic reactivity towards hydrophobic molecules such as polychlorinated biphenyls, while the smaller and more dispersed nanocrystals on a viable bacterial carrier exhibited high catalytic reactivity towards the reductive degradation of the anionic pollutant perchlorate.

Biodegradation, Environmental↗

Differential effects of the adenosine A(1) receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes.

The benzoylthiophene analog, PD 81,723, has been shown to allosterically enhance agonist binding and functional activation of the mammalian adenosine (ADO) A(1) receptor subtype by putatively maintaining the receptor in a high affinity state. The present studies were conducted to evaluate the ability of PD 81,723 to enhance the binding of [3H]cyclohexyladenosine ([3H]CHA) to A(1) receptors of neural (cerebral cortex) and non-neural (adipocyte) origin in three different species; rat, guinea pig and dog. PD 81, 723 (0.3-100 microM) produced a concentration-dependent enhancement of [3H]CHA binding to rat brain A(1) receptors. These effects were also species-dependent with larger enhancements (150-200% of control) observed in guinea pig and dog brain membranes as compared to the rat (120% of control). In contrast, PD 81,723 did not produce any enhancement of [3H]CHA binding to A(1) receptors in adipocyte membranes from any of the species examined. Additional binding studies were conducted using pharmacological manipulations that have previously been shown to enhance the allosteric effects of PD 81,723. In the presence of 1 mM GTP, the allosteric effects of PD 81,723 (15 microM) were increased in rat, guinea pig and dog brain membranes, however, in adipocyte membranes from each species, no significant alteration in agonist binding was observed. Similarly, the A(1) receptor selective antagonist 8-cyclopentyl-1, 3-dipropylxanthine (added to effectively reduce the intrinsic antagonist properties of PD 81,723) was found to enhance the allosteric effects of PD 81,723 (15 microM) in brain, but produce no alteration of agonist binding in adipocyte membranes from each species. Examination of the dissociation kinetics of [3H]CHA binding from rat brain and adipocyte membranes revealed that PD 81,723 (15 microM) differentially slowed agonist dissociation from brain, but not adipocyte, membranes. Taken together, the present data support the hypothesis that in tissues that are sensitive to PD 81,723, this benzyolthiophene functions to maintain the A(1) receptor in a high-affinity state and that the relative proportions of high-affinity A(1) receptors present in specific tissues may contribute, at least in part, to the apparent differential effects of PD 81,723 on agonist binding. The tissue specific modulation of A(1) receptor function by PD 81,723 also illustrates the possibility that the locus of allosteric modulation by PD 81,723 may be manifest via a specific, but indirect and tissue-dependent, interaction with the A(1) receptor.

Adenosine↗

Designing Pd-on-Au bimetallic nanoparticle catalysts for trichloroethene hydrodechlorination.

Alumina-supported palladium (Pd) catalysts have previously been shown to hydrodechlorinate trichloroethene (TCE) and other chlorinated compounds in water, at room temperature, and in the presence of hydrogen. The feasibility of this catalytic technology to remediate groundwater of halogenated compounds can be improved by re-designing the Pd material in order to increase catalytic activity. We synthesized and characterized Pd supported on gold nanoparticles (Au NPs) of different Pd loadings. In all cases, we found that these catalysts were considerably more active than Pd NPs, alumina-supported Pd, ard Pd-black (62.0, 12.2, and 0.42 L x g(Pd)(-1) x min(-1), respectively). There is a synergistic effect of the Pd-on-Au bimetallic structure, with the material with the highest TCE hydrodechlorination activity (943 L x g(Pd)(-1) x min(-1)) comprised of Au NPs partially covered by Pd metal. The Pd-on-Au bimetallic catalyst structure provides a new synthesis approach in improving the catalytic properties of monometallic Pd materials. The resulting nanoparticle-based materials should be highly suitable as hydrodehalogenation and reduction catalysts for the remediation of various organic and inorganic groundwater contaminants.

Catalysis↗

Nitrogen- vs Carbon-Coordination of the alpha-Cyano-Stabilized Phosphorus Ylide Ph(3)P=C(H)CN. X-ray Crystal Structure of {Pd(dmba)[P(OMe)(3)][N&tbd1;C-C(H)=PPh(3)]}(ClO(4)).

The reaction of the solvated complexes [Pd(C&arcraise;N)(PR'(3))(THF)](ClO(4)) [C&arcraise;N = 2-((dimethylamino)methyl)phenyl-C(1),N or dmba, 2-(1-(R)-(dimethylamino)ethyl)phenyl-C(1),N or (R)-dmphea; PR'(3) = PPh(3), P(OMe)(3)] with a stoichiometric amount of Ph(3)P=C(H)CN (CPPY) (1:1 molar ratio), in THF at low temperature, gives the cationic derivatives {Pd(C&arcraise;N)(PR'(3))[N&tbd1;C-C(H)=PPh(3)]}(ClO(4)), 4-6, in which the ylide ligand is N-coordinated to the Pd(II) center and trans to the ortho-metalated C(6)H(4) group, in an "end-on nitrile" coordination mode that is unprecedented for this ylide. The reaction of [Pd(C&arcraise;N)(NCMe)(2)](ClO(4)) (C&arcraise;N = dmba, (R)-dmphea) with Ph(3)P=C(H)CN (1:2 molar ratio) gives the bis(ylide) complexes [Pd(C&arcraise;N)(Ph(3)PCHCN)(2)](ClO(4)) (7, 8) in which one of the ylides is C-coordinated (trans to the NMe(2) group) and the other one is N-bonded (and trans to the C(6)H(4) group). Either by reaction of [Pd(C&arcraise;N)(NCMe)(2)](ClO(4)) with Ph(3)P=C(H)CN (1:1 molar ratio) or by reaction of the bis(ylide) complexes [Pd(C&arcraise;N)(Ph(3)PCHCN)(2)](ClO(4)) with [Pd(C&arcraise;N)(NCMe)(2)](ClO(4)) (1:1 molar ratio), very insoluble materials of stoichiometry [Pd(C&arcraise;N)(Ph(3)PCHCN)(ClO(4))] (9, 10) are obtained, which appear to be dinuclear derivatives with the ylide acting as a C,N-bridging group, [(C&arcraise;N)Pd(&mgr;-C,N-Ph(3)PCHCN)(2)Pd(C&arcraise;N)](ClO(4))(2). At the same time, this ylide is shown to be sufficiently nucleophilic to promote the bridge-splitting of the dinuclear [Pd(&mgr;-Cl)(C&arcraise;N)](2) complexes, giving the mononuclear derivatives [PdCl(C&arcraise;N)(Ph(3)PCHCN)] (11, 12) as a mixture of two isomers; in one of them, the ylide acts as a C-donor while in the other it acts as an N-donor. IR and NMR spectroscopies allow the unambiguous characterization of all of these products, and the X-ray crystal structure of {Pd(dmba)[P(OMe)(3)][N&tbd1;C-C(H)=PPh(3)]}(ClO(4)) (5) is reported. Complex 5 crystallizes in the monoclinic system, space group P2(1)/c, a = 12.5690(10) Å, b = 17.857(2) Å, c = 14.729(2) Å, beta = 92.560(10) degrees, Z = 4, V = 3302.5(6) Å(3), 4881 reflections with I > 2sigma(I) for the refinement of 423 parameters and 30 restraints, R1 = 0.0384, wR2 = 0.0961, and GOF = 1.044.

Journal Article↗

Refolding and characterization of recombinant human GST-PD-1 fusion protein expressed in Escherichia coli.

Programmed death-1 (PD-1) is a costimulatory molecule of CD28 family expressed on activated T, B and myeloid cells. The engagement of PD-1 with its two ligands, PD-L1 and PD-L2, inhibits proliferation of T cell and production of a series of its cytokines. The blockade of PD-1 pathway is involved in antiviral and antitumoral immunity. In this study, human PD-1 cDNA encoding extracellular domain was amplified and cloned into expression plasmid pGEX-5x-3. The fusion protein GST-PD-1 was effectively expressed in E. coli BL21 (DE3) as inclusion bodies and a denaturation and refolding procedure was performed to obtain bioactive soluble GST-PD-1. Fusion protein of above 95% purity was acquired by a convenient two-step purification using GST affinity and size exclusion columns. Furthermore, a PD-L1-dependent in vitro bioassay method was set up to characterize GST-PD-1 bioactivity. The results suggested that GST-PD-1 could competently block the interaction between PD-L1 and PD-1 and increase the production of IL-2 and IFN-gamma of phytohemagglutinin-activated T cells.

Animals↗

In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor.

PD-198961, 3-(4-5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl)-4-hydroxybenzenecarboximidamide, is a novel, synthetic factor Xa inhibitor with a Ki of 2.7 nM against human factor Xa. The aim of the present study was to evaluate the pharmacokinetic profile and antithrombotic efficacy of PD-198961 in rabbits. When tested in vitro, PD-198961 doubled prothrombin time (PT) and activated partial thromboplastin time (aPTT) at concentrations of 0.13 and 0.32 microM in human plasma, 0.2 and 0.09 microM in rabbit plasma, 0.3 and 0.4 microM in dog plasma, respectively. Intravenous administration of PD-198961 at 1 mg/kg over 30 minutes resulted in a maximal prolongation in PT and aPTT of 4.9 +/- 0.4 and 4.1 +/- 0.9-fold of baseline, respectively. The peak plasma concentration of PD-198961 was 977 +/- 96 ng/ml. The anticoagulant effect of PD-198961 was readily reversible; coagulation parameters and plasma concentration returned to near baseline 15 minutes after cessation of infusion. There was a good correlation between PT prolongation and plasma concentration of PD-198961 (r = 0.93). In an FeCl3-induced model of arterial thrombosis in rabbits, the antithrombotic effects of PD-198961 were compared with that of LB-30057, a direct thrombin inhibitor, and enoxaparin, a low molecular weight heparin (LMWH). PD-198961 dose dependently increased the time to occlusion (TTO), reduced thrombus weight (TW), and decreased the incidence of occlusion. When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01). PD-198961 also dose dependently inhibited ex vivo plasma FXa activity. At the highest dose tested, PD-198961 increased aPTT to 1.4 +/- 0.1-fold of baseline (compared with 1.5 +/- 0.1 and 2.8 +/- 0.3-fold of baseline for LB-30057 [CI-1028] and enoxaparin, respectively), and had modest effects on bleeding time (< or = 2-fold). These results indicate that PD-198961 is a potent FXa inhibitor and an effective antithrombotic agent at doses that produce only modest changes in normal hemostasis.

Animals↗

Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.

PD 118717 (7-[3-[4-(2-pyrimidinyl)-1-piperazinyl]-propoxy]-2H-1- benzopyran-2-one sulfate) proved to be a dopamine (DA) D-2 autoreceptor agonist in biochemical and electrophysiological studies in rats and to exhibit an antipsychotic-like profile in behavioral tests in rodents and monkeys. In vitro binding studies indicated that PD 118717 bound selectively to DA D-2 vs. D-1 receptors and exhibited agonist binding properties (biphasic inhibitory curves and GTP shift) similar to DA. It also had significant affinity for serotonin-(5-HT)1A but not 5-HT1B and 5-HT2 receptors. PD 118717 was active in antagonizing the tau-butyrolactone-induced accumulation of dopa in rat striatum and mesolimbic regions. PD 118717 also depressed the firing of DA neurons in substantia nigra pars compacta of rats. In both of the latter tests the effects of PD 118717 were reversed by haloperidol. PD 118717 decreased brain DA metabolism, decreased DA utilization, decreased accumulation of dopa after inhibition of L-aromatic amino acid decarboxylase, stimulated serum corticosterone and inhibited stimulated serum prolactin levels. PD 118717 did not alter striatal acetylcholine levels; nor did it induce locomotor stimulation or stereotypy in normal animals, suggesting a lack of postsynaptic DA stimulation of normosensitive DA receptors. In tests designed to reveal even weak postsynaptic DA agonist effects, PD 118717 stimulated locomotor activity in 6-hydroxydopamine-lesioned animals and relatively higher doses induced a low degree of stereotyped behavior when combined with the DA D-1 agonist SKF 38393. PD 118717 decreased the accumulation of 5-hydroxytryptophan in brain, an effect probably due to an agonist action at 5-HT1A receptors. PD 118717 decreased spontaneous locomotor activity in rodents, antagonized amphetamine-stimulated hyperactivity in mice and inhibited Sidman avoidance in monkeys, effects seen with antipsychotic agents. Unlike DA antagonist antipsychotics, PD 118717 did not induce extrapyramidal dysfunction in monkeys. PD 118717 displayed behavioral activity after p.o. dosing and its effects did not show tolerance on repeated dosing. In conclusion, PD 118717 has the profile of a DA autoreceptor agonist in neurochemical and neurophysiological tests and produces effects suggestive of antipsychotic efficacy without neurological side effect liability in preclinical behavioral tests.

Animals↗

[Studies on Au-Ag-Pd-Cu alloys. (Part 2) Some properties on alloys containing 30 wt% Au (author's transl)].

In the previous paper, the author reported 30 wt% Au was more favourable content in Au-Ag-Pd-Cu quaternary dental alloys. In this paper, the experiment was carried out to find suitable Pd and Cu content in 30 wt% Au-Ag-Pd-Cu alloy. Pd and Cu content was changed from 5 wt% to 25 wt% and from 10 wt% to 20 wt% respectively. Ag content was balanced, and no other metals was added. Range of solidification temperature, tensile strength, elongation, hardness, corrosion resistivity and castability were tested. Results were as follows. 1) In these alloys, liquidus points were in the range of 880 degree C approximately 140 degree C, but in the majority of alloys, liquidus points were under 1100 degree C. Range of solidification temperature was more narrow in 20 wt% Cu than other Cu content. 2) The tensile strength and elongation of swaged specimens increased as Pd content increased, but in case of cast specimens, mechanical properties were the highest at 15 approximately 20 wt% Pd. The Vicker's hardness was in the range of 116 to 235. 3) The corrosion test in 0.1% Na2S solution indicated that the corrosion resistance was increased with Pd content and alloys contained more than 20 wt% Pd showed good resistance to corrosion. 4) The castability was affected by the Pd content and much decreased between 15 wt% Pd and 20 wt% Pd, but the castability of these alloys is twice as good as the alloys on the market. From these results, it seemed that the alloys containing 15 approximately 20 wt% Pd and 15 approximately 25 wt% Cu were more favourable composition to 30 wt% Au-Ag-Pd-Cu alloys.

Copper↗

Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX): a multifunctional protein involved in central nervous system development and disease.

Phosphodiesterase-Ialpha/autotaxin (PD-Ialpha/ATX) was originally identified as a cell-motility-stimulating factor secreted by a variety of tumor cells. Thus, studies related to its potential functional roles have traditionally focused on tumorigenesis. PD-Ialpha/ATX's catalytic activity, initially defined as nucleotide pyrophosphatase/phosphodiesterase, was soon recognized as being necessary for its tumor cell-motility-stimulating activity. However, only the discovery of PD-Ialpha/ATX's identity with lysophospholipase D, an extracellular enzyme that converts lysophosphatidylcholine into lysophosphatidic acid (LPA) and potentially sphingosylphosphoryl choline into sphingosine 1-phosphate (S1P), revealed the actual effectors responsible for PD-Ialpha/ATX's ascribed motogenic functions, i.e., its catalytic products. PD-Ialpha/ATX has also been detected during normal development in a number of tissues, in particular, the central nervous system (CNS), where expression levels are high. Similar to tumor cells, PD-Ialpha/ATX-expressing CNS cells secrete catalytically active PD-Ialpha/ATX into the extracellular environment. Thus, it appears reasonable to assume that PD-Ialpha/ATX's CNS-related functions are mediated via lysophospholipid, LPA and potentially S1P, signaling. However, recent studies identified PD-Ialpha/ATX as a matricellular protein involved in the modulation of oligodendrocyte-extracellular matrix interactions and oligodendrocyte remodeling. This property of PD-Ialpha/ATX was found to be independent of its catalytic activity and to be mediated by a novel functionally active domain. These findings, therefore, uncover PD-Ialpha/ATX, at least in the CNS, as a multifunctional protein able to induce complex signaling cascades via distinct structure-function domains. This Mini-Review describes PD-Ialpha/ATX's multifunctional roles in the CNS and discusses their potential contributions to CNS development and pathology.

Animals↗

The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis.

Recently, the involvement of immune responses in metabolic bone disease and/or local bone destruction has received much attention. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a member of the immunoglobulin (Ig) superfamily, negatively regulates T cell activation. The deficiency of CTLA-4 induces profound osteopenia with an increase in osteoclastogenesis, suggesting the important role of activated T cells in osteoclastogenesis. Programmed death-1 (PD-1) is the newly identified immunoregulatory receptor, which also belongs to the Ig superfamily. Both CTLA-4 and PD-1 are induced on activated T cells, however, there are no reports linking PD-1 with osteoclasts. In the present study, we have examined the bone phenotype in PD-1-deficient mice PD-1-/- and the role of PD-1 in osteoclastogenesis and osteoclast function. Both trabecular and cortical bone mineral densities of tibia were significantly increased, as observed in peripheral quantitative computed tomography (pQCT), at 12 weeks of age in PD-1-/- mice. Histomorphometric analysis of the PD-1-/- mice and the age-matched controls at 12 weeks of age showed a 2-fold increase in bone volume (BV/TV) with a 55% decrease in osteoclast number (N.Oc/BS). Bone formation indices were similar in both groups. The number of soluble receptor activator of nuclear factor kappaB ligand (sRANKL)-induced osteoclast-like cells (OCLs) derived from the PD-1-deficient splenocytes was significantly decreased (by 25%). On the other hand, PD-1 deficiency did not affect the bone-resorbing activity of mature osteoclasts. Our results suggest that PD-1 deficiency reduces osteoclastogenesis resulting in an osteopetrotic phenotype. Identical members of the Ig superfamily, CTLA-4 and PD-1, which negatively regulate immune responses, may differentially affect osteoclastogenesis and bone remodeling.

Animals↗

The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography.

In this study we have explored the nature and range of sleep dysfunction that occurs in untreated Parkinson's disease (PD) comparing data obtained from the use of the Parkinson's disease sleep scale (PDSS) in an untreated PD patient group compared to advanced PD and healthy controls. 25 untreated (drug-naive, DNPD) PD patients (mean age 66.9 years, range 53-80, 18 males) completed the validated Parkinson's disease sleep scale (PDSS), mean duration of PD was 2.1 years (1-10, up to 4 years in all except one patient with tremulous PD reporting tremor duration of 10 years) and mean Hoehn and Yahr score 1.9 (1-3). Data were compared to 34 advanced PD (mean age 70.2 years, range 51-88, 23 male), mean duration of PD 11 years (range 4-22), mean Hoehn and Yahr score 3.4 (3-5) and PDSS data obtained from 131 healthy controls (mean age 66.6 years, range 50-93, 56 males). Total PDSS scores and PDSS sub-items, except PDSS item 2, were highly significantly different (p<0.001) between DNPD, advanced PD and controls. Controls reported higher mean PDSS scores than both groups of patients, and advanced cases reported lower (mean+/-S.D.) PDSS scores (86.95+/-20.78) than drug-naive (105.72+/-21.5) (p<0.001). Logistic regression analysis showed that items PDSS8 (nocturia), PDSS11 (cramps), PDSS12 (dystonia), PDSS13 (tremor), and PDSS15 (daytime somnolence) were significantly impaired in DNPD compared to controls while PDSS7 (nighttime hallucinations) additionally separated advanced PD from DNPD. In a subgroup of 11 advanced PD cases (mean age 62 years, range=49-84 years, mean Hoehn and Yahr score 2.5, range=1-3) with high Epworth Sleepiness Scale (ESS) scores (mean 14.5), low item 15 PDSS score (mean 4.7) and complaints of severe daytime sleepiness, underwent detailed overnight polysomnography (PSG) studies, all showing abnormal sleep patterns. We conclude that nocturia, nighttime cramps, dystonia, tremor and daytime somnolence seem to be the important nocturnal disabilities in DNPD and some of these symptoms may be reminiscent of "off" period related symptoms even though patients are untreated. Furthermore, polysomnography in "sleepy" PD patients may help diagnose unrecognised conditions such as periodic limb movement of sleep (PLMS), obstructive sleep apnoea (OSA) and REM Sleep Behaviour Disorder.

Aged↗

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

PD 158771 has been described in receptor binding and biochemical tests as a partial agonist at dopamine (DA) D2 and D3 receptors as well as an agonist at serotonin (5-HT)(1A) receptors. The present studies describe the profile of PD 158771 in rodent and primate behavioral tests. PD 158771 reduced spontaneous locomotor activity in mice (ED(50)=0.38 mg/kg, i.p.) and rats (ED(50) = 1.2 mg/kg, i.p. and 0.16 mg/kg, s.c.), and reduced amphetamine-stimulated locomotion in mice (ED(50) = 0.13 mg/kg, i.p.). At relatively higher doses up to 3 mg/kg, s.c. in rats, PD 158771 did not produce locomotor stimulation or induce stereotypy, indicating a lack of postsynaptic DA agonist activity. PD 158771 reduced apomorphine stimulated locomotion in rats at a dose 4.6-fold greater than those that reduced spontaneous locomotor activity, indicating weak postsynaptic DA antagonist actions; results consistent with a partial agonist profile. PD 158771 produced anxiolytic-like effects in the water-lick (Vogel) conflict test, effects possibly due to the 5-HT(1A) activity. However, PD 158771 was inactive in the water wheel behavioral despair model in rats, indicating lack of antidepressant properties. Similar to known antipsychotics, PD 158771 produced a potent and long-lasting inhibition of conditioned avoidance responding in squirrel monkeys. In contrast to standard antipsychotics, and similar to clozapine, PD 158771 did not cause catalepsy in rats at a dose 20-fold higher than the ED(50) dose for locomotor inhibition. PD 158771 also had a somewhat lower liability than haloperidol to produce extrapyramidal dysfunction in squirrel and cebus monkeys sensitized to the dystonic effects of haloperidol. The data indicate that PD 158771 is a DA partial agonist with weak intrinsic activity that selectively activates brain DA autoreceptors. PD 158771 produced behavioral effects consistent with potential antipsychotic and anxiolytic efficacy, and has an improved profile in the extrapyramidal side effect model when compared to certain currently available antipsychotic agents.

Animals↗

Dealloying and electroformation in high-Pd dental alloys.

OBJECTIVE: The corrosion of high-Pd dental alloys, depending on their composition, is postulated to be associated with dealloying and electroformation. The aim of this study was to obtain additional information to support these postulations. METHODS: The corrosion characteristics of two commercial high-Pd alloys, Naturelle (79Pd-10Cu-2Au-9Ga wt%) and Rx 91 (54Pd-37Ag-9Sn), and their elemental components were evaluated in a phosphated buffer saline (PBS) solution. Indium, a common element in high-Pd alloys, was also included. The corrosion characteristics measured for each material were the 24 h open circuit potential (OCP) and the potentiodynamic anodic polarization curve. Additionally, the surface composition of the two alloys, before and after immersion corrosion in PBS for 2 months, was analyzed by X-ray photo electron spectroscopy (XPS). RESULTS: Of the pure metals, Ga had the most electroactive OCP followed in order by In, Sn, Cu, Ag, Au, and Pd. The anodic polarization data showed all base metals to be unstable in PBS. The electroformation of AgCl was evidenced in the polarization curve of pure Ag. Both electrochemical characteristics of the PdCu-based alloy were very similar to that of pure Pd. The PdAg-based alloy displayed corrosion behavior resembling that of Ag. XPS data showed that the corrosion of the PdCu-based alloy was associated with a decrease in surface content of Cu and Ga but an increase in Pd and Au. The PdAg-based alloy surface during corrosion showed a decrease in Sn, an increase in Ag, and an unaltered Pd content. The behavior of the PdCu-based alloy is attributed to the operation of a galvanic interaction that causes dissolution of base metals and surface enrichment with primarily Pd. Dealloying, Ag-enrichment, and AgCl formation are thought to have contributed to the observed behavior of the PdAg-based alloy. These mechanisms are consistent with data from published ion release studies. SIGNIFICANCE: The allergenic potential of any Pd alloy is dependent on its propensity to develop a Pd-rich surface and thus release Pd+2 ions. The present study, though limited, has shown that electrochemical characteristics, namely OCP and polarization curves, can be used to identify such alloys. Further studies are warranted to evaluate the widespread applicability of these characteristics in distinguishing between Pd alloys that are biologically safe and those that are not.

Copper↗

Structural investigation of Pd(II) in concentrated nitric and perchloric acid solutions by XAFS.

XAFS spectra of palladium(II) in concentrated HNO3/HClO4 acid mixtures have been recorded and analyzed. Structural parameters of the Pd(H2O)4(2+) complex and the mixed nitric Pd(NO3)2(H2O)2 complex, for the first time, were determined by the XAFS method. For pure 5 M HClO4 and for mixtures (0-0.3 M HNO3), the XAFS spectra of the 0.02 M Pd solutions are indeed very similar and originated from four Pd-O(w) equivalent distances. For the Pd(H2O)4(2+) square-planar aqua ion in strong perchloric acid, the use of an FEFF6 theoretical approach led to a first-shell Pd-O(w) distance of 2.00 (1) A and a Debye-Waller (DW) factor of sigma2 = 0.0030 (3) A2. Four water molecules are tightly bound to the Pd2+ ion in the equatorial plane, while two (or one) axial water molecules are weakly bound to the metal ion at 2.5 A with a DW factor of 0.015 (5) A2. For highly concentrated mixtures (4-6 M HNO3) and for pure concentrated (4-6 M) nitric acid as well as for crystalline powder Pd(NO3)2(H2O)2, the XAFS spectra are very similar and are determined by the mixed nitric complex Pd(NO3)2(H2O)2: four Pd-O near-equivalent distances of 2.01 (1) A from two H2O and two NO3 molecules with a total DW factor of sigma2 = 0.0037 (3) A2. Moreover, two Pd---N distances of 2.8-2.9 A were determined in the second coordination shell. Finally, for intermediate mixtures (1-3 M HNO3 in 5 M HClO4), the XAFS spectra are a superposition of the XAFS of Pd(H2O)4(2+) and Pd(NO3)2(H2O)2 complexes. The mean ligand number NO3(-) around Pd2+ has been calculated, and the XAFS results at pH close to zero confirm the spectrophotometric results previously published.

Journal Article↗

Surface state and composition of a disperse Pd catalyst after its exposure to ethylene.

Pd black was exposed to ethylene alone or in its mixture with hydrogen at 300 and 573 K. The samples were investigated by X-ray photoelectron spectroscopy (XPS) and ultraviolet photoelectron spectroscopy (UPS). Room temperature introduction of C(2)H(4) (also in the presence of H(2)) induced a binding-energy (BE) shift in the Pd 3d doublet and changed its full width at half-maximum (fwhm). The UPS features indicate shifting of electrons from the Pd d-band to Pd-H, Pd-C, and even Pd-OH species. Vinylidene (BE approximately 284.1 eV) may be the most abundant individual surface species on disperse Pd black, along with carbon in various stages of polymerization: "disordered C" (BE approximately 284 eV), graphite (approximately 284.6 eV), and ethylene polymer (approximately 286 eV), and also some "atomic" C (BE approximately 283.5 eV). Introduction of H(2) followed by ethylene brought about stronger changes in the state of Pd than exposure in the reverse sequence. This may indicate that the presence of some surface C may hinder the decomposition of bulk PdH. Formation of Pd hydride was blocked when ethylene was introduced prior to H(2). The C 1s intensity increased, the low-binding-energy C components disappeared, and graphitic carbon (BE approximately equal to 284.6 eV) prevailed after ethylene treatment at 573 K. The loss of the Pd surface state and "PdH" signal were observed in the corresponding valence band and UPS spectra. Hydrogen treatment at 540 K was not able to decrease the concentration of surface carbon and re-establish the near-surface H-rich state. UPS showed overlayer-type C in these samples. The interaction of Pd with components from the feed gas modified its electronic structure that is consistent with lattice strain induced by dissolution of carbon and hydrogen into Pd, as indicated by the d-band shift and the dilution of the electron density at E(F).

Journal Article↗

Formation of bimetallic Ag-Pd nanoclusters via the reaction between Ag nanoclusters and Pd2+ ions.

We have investigated systematically the mechanistic aspects of the Ag-Pd bimetallic cluster formation within sodium bis(2-ethylhexyl)sulfosuccinate (AOT) reverse micelles by using in-situ X-ray absorption spectroscopy (XAS). A two-step sequential reduction method is employed for the synthesis of Ag-Pd bimetallic clusters. The first step involves preparation of Ag nanoclusters, by mixing the Ag+ ions containing the AOT microemulsion system with a reducing agent hydrazine (N2H4) containing the AOT microemulsion system. In the second step, the addition of Pd2+ ions to Ag nanoclusters led to the formation of Ag-Pd bimetallic clusters via the reaction between Ag nanoclusters and Pd2+ ions in AOT reverse micelles. The reduction of silver ions and the formation of corresponding Ag nanoclusters are monitored as a function of the dosage of the reducing agent, hydrazine. In-situ XAS allowed probing of the reaction between Ag nanoclusters and Pd2+ ions during the formation of Ag-Pd bimetallic clusters. Analysis of Ag and Pd K-edge XAS spectra reveals that in the final stage Ag-Pd clusters, in which "Ag" atoms prefer to be surrounded by "Pd" and "Pd" atoms prefer to be surrounded by "Pd", were formed. On the basis of XAS results presented here, we are able to propose a structural model for each step so that this work provides a detailed insight into the mechanism of nucleation and growth of Ag-Pd bimetallic clusters. We also discussed the atomic distribution of Ag and Pd atoms in Ag-Pd bimetallic clusters based on the calculated XAS structural parameters.

Journal Article↗